SCHEDULE: Nantahala Capital Management Acquires 8.22% Stake in Fulcrum Therapeutics

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 5,475,040 shares, representing 8.22% of Fulcrum Therapeutics, Inc.'s common stock as of June 30, 2026.

Summary

• Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has filed a Schedule 13G.
• As of June 30, 2026, the Reporting Persons collectively beneficially own 5,475,040 shares of Fulcrum Therapeutics, Inc. common stock.
• This ownership stake represents 8.22% of the total outstanding shares.
• The filing indicates shared voting and dispositive power over these shares.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not overwhelming stake acquisition by an investment firm, with no immediate red flags.

Positives

• Significant stake acquired by Nantahala Capital Management, indicating confidence in Fulcrum Therapeutics.
• The stake of 8.22% is substantial and could signal potential future engagement or influence.
• The filing is routine and does not indicate any immediate negative actions or concerns from the reporting persons.

Negatives

• No specific financial performance data or company updates are provided in this filing, as it is a disclosure of beneficial ownership.
• The filing does not offer insight into the reporting persons' intentions beyond ordinary course of business.

Risks

• Potential for increased market volatility if Nantahala Capital Management decides to significantly alter its position.
• Future actions by Nantahala Capital Management could impact Fulcrum Therapeutics' stock price and strategic direction.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Fulcrum Therapeutics.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms like Nantahala Capital Management are common in the biotechnology and pharmaceutical sectors, often signaling a belief in the company's pipeline or market potential. This filing places Fulcrum Therapeutics within the typical landscape of companies attracting institutional investor interest.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by Nantahala Capital Management may be viewed positively by some shareholders, potentially indicating increased institutional interest and support for the company.
• Management: The company's management will be aware of Nantahala's substantial ownership, which could influence future strategic decisions and communications.

Next Steps

• Nantahala Capital Management will continue to hold its shares in Fulcrum Therapeutics.
• Further filings may be required if Nantahala Capital Management's ownership stake changes significantly.

Key Dates

Keywords

Fulcrum Therapeutics, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Shareholder